Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 7/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 7/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 7/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | NQO1 | P15559 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763157 | 0.82 | CSNK2A2 (0.50) | NPC1RAB9ACSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL17254780 | 0.81 | MAOB (0.46) | NPC1RAB9AKDM4ETP53ALDH1A1 | |
| SCHEMBL9608562 | 0.76 | RAB9A (0.68) | NPC1RAB9AKDM4ETP53ALDH1A1 | |
| SCHEMBL11320611 | 0.73 | NPC1 (0.59) | NPC1RAB9AKDM4ETP53ALDH1A1 | |
| SCHEMBL311433 | 0.73 | ALOX5 (0.58) | NPC1RAB9AKDM4ETP53ALDH1A1 | |
| SCHEMBL9608577 | 0.73 | GPR119 (0.52) | NPC1RAB9AKDM4ETP53ALDH1A1 | |
| SCHEMBL17254783 | 0.73 | MAOB (0.59) | NPC1RAB9ACSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL311263 | 0.73 | ESR1 (0.61) | NPC1RAB9ACSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL7600946 | 0.72 | ELANE (0.54) | NPC1RAB9ACSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL5307439 | 0.71 | NPC1 (0.60) | NPC1RAB9AKDM4ETP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723742-B2 | TREATMENT OF DISEASES WHICH CAUSE EXCESS OF IRON IN HUMAN OR ANIMAL BODY OR ARE CAUSED BY IT | NOVARTIS AG. (CH) | 2004-04-20 | — | — | US | disclosed |
| US-20030203954-A1 | Substituted 3, 5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators | LATTMANN RENE (CH) | 2003-10-30 | — | — | US | disclosed |
| US-6596750-B2 | Compounds have useful pharmaceutical properties and are particularly active as iron chelators. They can be used for the treatment of iron overload in warm-blooded animals. | NOVARTIS AG (CH) | 2003-07-22 | — | — | US | disclosed |
| US-20030069273-A1 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators | LATTMANN RENE (CH) | 2003-04-10 | — | — | US | disclosed |
| EP-0914118-B1 | SUBSTITUTED 3,5-DIPHENYL-1,2,4-TRIAZOLES AND THEIR USE AS PHARMACEUTICAL METAL CHELATORS | NOVARTIS AG (CH) | 2002-10-23 | — | — | EP | disclosed |
| US-6465504-B1 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators | NOVARTIS AG (CH) | 2002-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069273-A1 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators | TFRC, SLC40A1, FECH | NPC1 2448/4885RAB9A 2542/4885CSNK2A2 4369/4885 |
| US-20030203954-A1 | Substituted 3, 5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators | TFRC, SLC40A1, FECH | NPC1 2448/4885RAB9A 2542/4885CSNK2A2 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.